Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lessened its stake in shares of Pulmonx Co. (NASDAQ:LUNG - Free Report) by 72.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 83,370 shares of the company's stock after selling 217,991 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.21% of Pulmonx worth $566,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in LUNG. BNP Paribas Financial Markets acquired a new position in Pulmonx in the fourth quarter worth approximately $43,000. R Squared Ltd acquired a new stake in shares of Pulmonx during the 4th quarter valued at $46,000. Stifel Financial Corp bought a new position in shares of Pulmonx during the 4th quarter valued at $81,000. SG Americas Securities LLC raised its holdings in shares of Pulmonx by 27.0% during the 4th quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock valued at $106,000 after purchasing an additional 3,310 shares in the last quarter. Finally, Graham Capital Management L.P. raised its holdings in shares of Pulmonx by 73.3% during the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company's stock valued at $123,000 after purchasing an additional 7,641 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company's stock.

Insider Buying and Selling at Pulmonx

In other news, CFO Mehul Joshi sold 14,384 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.12, for a total transaction of $102,414.08. Following the completion of the sale, the chief financial officer now owns 113,986 shares of the company's stock, valued at $811,580.32. This represents a 11.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glendon E. French III sold 55,453 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total transaction of $459,150.84. Following the sale, the director now directly owns 1,011,974 shares of the company's stock, valued at $8,379,144.72. This represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 145,660 shares of company stock valued at $1,128,484. Corporate insiders own 6.80% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LUNG shares. D. Boral Capital reiterated a "buy" rating and set a $17.00 price target on shares of Pulmonx in a report on Thursday, May 1st. Jefferies Financial Group assumed coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a "buy" rating on the stock. Morgan Stanley began coverage on shares of Pulmonx in a research report on Monday, March 10th. They set an "equal weight" rating on the stock. Citigroup started coverage on shares of Pulmonx in a research report on Monday, March 10th. They issued a "buy" rating on the stock. Finally, Canaccord Genuity Group reduced their target price on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Pulmonx has an average rating of "Moderate Buy" and a consensus price target of $12.07.

Pulmonx Trading Up 0.3%

LUNG opened at $3.43 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The company has a market cap of $138.08 million, a price-to-earnings ratio of -2.38 and a beta of 0.65. The firm has a 50 day simple moving average of $5.50 and a 200 day simple moving average of $6.33. Pulmonx Co. has a fifty-two week low of $3.18 and a fifty-two week high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.01. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The firm had revenue of $22.54 million during the quarter, compared to the consensus estimate of $22.03 million. On average, sell-side analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Want to see what other hedge funds are holding LUNG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulmonx Co. (NASDAQ:LUNG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.